N/A
Completed N=536
DeADT - Living Well With Prostate Cancer
Source: ClinicalTrials.gov NCT06199986 ↗Enrolled (actual)
536
Serious AEs
—
Results posted
Jun 2025
Primary outcomePrimary: Effectiveness - Interruption in Low Value ADT Injection (i.e., Take a Break From ADT) — 12; 28; 24 Participants
Summary
The goal of this randomized de-implementation trial is to compare two strategies to reduce low-value androgen deprivation therapy (ADT) use for prostate cancer care. The aim of the study is to compare implementation of the two strategies: use of a clinical reminder order check intervention versus a provider script/patient education approach, and their impacts on low-value ADT use after six months. The main goal of both interventions will be to decrease ADT overuse for patients with prostate cancer, but to do this in a way that is acceptable to the clinicians who treat these patients. The interventions will be initiated for providers only across 4 participating facilities. Provider participants will engage with one of the interventions triggered in the electronic health record when their patients are deemed likely to be receiving low-value ADT. Each provider participant receives only one of the interventions. The intervention is triggered for every clinic visit involving a patient deemed to be receiving low-value ADT, so provider participants may receive their assigned intervention multiple times. Researchers will compare provider use of both strategies to determine implementation outcomes and whether one was more effective in reducing low-value ADT use.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effectiveness - Interruption in Low Value ADT Injection (i.e., Take a Break From ADT) |
12; 28; 24 | — |
| SECONDARY Reach |
100; 100 | — |
| SECONDARY Penetration - ADT Order Check Attestation (OR) Intervention |
— | — |
| SECONDARY Penetration - Provider Script (SC) Intervention |
64 | — |
| SECONDARY Feasibility - Site Level: Medical Center Director (MCD) Approval |
2; 2 | — |
| SECONDARY Feasibility - Site Level: Fully Operationalized Intervention |
2; 2 | — |
| SECONDARY Feasibility - Clinic Level Activation: Clinics With Intervention Implementation |
0; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Any provider at participating sites who prescribes ADT for prostate cancer patients
Exclusion Criteria
- Providers opting out of study
Data sourced from ClinicalTrials.gov (NCT06199986). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.